| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 35.57 mm | 35.57 mm | 35.57 mm | 35.57 mm | 35.57 mm | 35.57 mm |
| Cash burn (monthly) | 5.80 mm | 2.96 mm | 6.14 mm | 3.76 mm | 5.52 mm | 3.16 mm |
| Cash used (since last report) | 168.53 mm | 85.94 mm | 178.34 mm | 109.40 mm | 160.33 mm | 91.83 mm |
| Cash remaining | -132.96 mm | -50.37 mm | -142.77 mm | -73.83 mm | -124.76 mm | -56.27 mm |
| Runway (months of cash) | -22.9 | -17.0 | -23.3 | -19.6 | -22.6 | -17.8 |
| 13F holders | Current |
|---|---|
| Total holders | 6 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 9.40 mm |
| Total shares | 2.70 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| GSK GSK | 803.92 k | $973.00 k |
| Cooperatieve AESCAP Venture I U.A. | 615.64 k | $4.09 mm |
| Atlas Venture Opportunity Fund I | 599.52 k | $3.01 mm |
| Atlas Venture Fund VII L P | 575.00 k | $696.00 k |
| MKGAF Merck KGaA | 75.14 k | $377.00 k |
| Biotechnology Value Fund L P | 25.84 k | $255.00 k |
| Proequities | 0.00 | $0.00 |
